Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Terminated × NIS-793 × Clear all

Phase

Phase 2 2 Phase 1 1

Status

Withdrawn 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 94 pembrolizumab 72 Gemcitabine 69 fludarabine 59 Carboplatin 54 Nivolumab 50 Paclitaxel 46 Radiotherapy 45 Rituximab 44 Docetaxel 44 Cisplatin 44 Lenalidomide 37 Dexamethasone 36 Ipilimumab 34 Etoposide 31 Cytarabine 31 Temozolomide 29 Radiation 29 Azacitidine 28 Bevacizumab 26 venetoclax 25 Bortezomib 24 Capecitabine 23 Pemetrexed 22 atezolizumab 21 Oxaliplatin 21 Magnetic Resonance Spectroscopy 21 Irinotecan 21 fludarabine phosphate 20 Cetuximab 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05417386 2025-11-18

FOLFIRINOX + NIS793 in Pancreatic Cancer

Massachusetts General Hospital

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡